anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an anorectic or a dieting method of safely and healthfully acquiring a slimming effect and a device for appetite suppression which enable safe self-control of appetite without the user's mentally and physically feeling a burden or side effects due to its use, that is, appropriately can suppress appetite without requiring extravagant efforts and burdens.  <P>SOLUTION: The anorectic contains, as an active agent, an aqueous solvent extract of Veronia cinerea Less. or Veronia cinerea Less. and Morus as an active ingredient. The dieting method comprises evaporating the liquid component of the anorectic and sucking the formed vapor with a respirator by a person wishing to diet. The active ingredient is odorless and is not orally absorbed by the digestive organs and is directly taken in the blood from the respirator or the like through the lungs, the nasal mucous membrane and the like. Accordingly, the active ingredient supports the consciousness of dieting through the central nerve to exert appetite suppression on the people wishing to diet for reducing the body weight, and as a result, a slimming effect appears but there is no slimming effect for the people unconscious of dieting.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Older age is linked with poorer self-care in the chronic kidney disease (CKD) setting. Informal health supporters (family members and friends) are critical sources of self-care support, but much remains unclear about the characteristics and implications of received support among this patient population. We examined how received self-care support (amount and type) related to positive (CKD management self-efficacy) and negative (depressive symptoms) psychosocial health correlates of self-care in 536 adults aged 65 years and older with non-dialysis-dependent CKD. Participants who received a greater amount of support reported less CKD management self-efficacy and more depressive symptoms. We did not observe associations between self-care support type and psychosocial health. Further research is needed to clarify our findings, especially studies that investigate causality and contextual influences.
Patients in the real stimulation group will receive rTMS treatment to the motor cortex (M1) of the affected hemisphere at a frequency of 5 Hz, once a day for 3 weeks and a total of 15 sessions. The application will be performed with Neurosoft-Neuro MS / D device. Before each session, the patient's resting motor threshold (RMT) value will be determined. RMT will be detected by obtaining a motor evoked potential of \>50 μV amplitude on electromyography recording of the contralateral first dorsal interosseous muscle in at least five out of 10 stimulations to the primary motor cortex.The stimulus intensity to be used in the treatment will be set as 90% of the motor threshold for the affected motor cortex and 100% of the motor threshold for the unaffected motor cortex.One session of stimulation will last for a total of 20 minutes and a total of 1000 pulses in the form of 5 Hz stimulation.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).The most important reason for the limited success obtained in the treatment and prevention so far is most likely related to the limited knowledge about its cause and pathogenesis of MS.One of the recent proposed mechanism for autoimmunity base of MS is Th1/Th2 implance of as well as other inflammatory and anti-inflammatory T cell such as Th17 and Treg and their releasing cytokines. Therefore the control of cytokine production may become potential therapeutic targets and modulation of the Th1/Th2 balance may provide a new pharmacological tool to treat this disease. Vitamin A (VA) or VA-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. high level dietary vitamin A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine production. Retinoic acid inhibits IL 12 production in activated macrophages, and RA pretreatment of macrophages reduces IFNγ production and increases IL4 production in antigen primed CD4 T cells. Supplemental treatment with vitamin A or retinoic acid (RA) decreases IFNγ and increases IL5, IL10, and IL4 production. Thus, vitamin A deficiency biases the immune response in a Th1 direction, whereas high level dietary vitamin A may bias the response in a Th2 direction.
Psychoeducational and self-care training, pain management, and emotional control, conducted in groups and aimed at patients with non-cancer chronic pain. Therapies applied: relaxation, meditation, cognitive-behavioral therapy, acceptance and commitment therapy, coaching, healthy eating, physical exercise, improving self-esteem, forgiveness technique. This group starts and successfully completes the workshop. A patient is considered to have successfully completed if they: Attend at least 4 out of the 5 sessions; complete all the initial documentation, at the end of the workshop, and at the 3-month mark; perform daily tracking of the 3 mandatory activities throughout the duration of the workshop.
BACKGROUND: Although there are models predicting epilepsy recurrence under different clinical conditions, few studies have examined blood biomarkers. Inflammation plays a crucial role in the occurrence and development of epilepsy. We analyzed inflammatory mediators in a regional hospital-based epilepsy cohort and investigated their relationship with subsequent epilepsy recurrence.
METHODS: Interictal inflammatory mediators were measured in 128 patients diagnosed with epilepsy participating in a prospective study. Inflammatory mediators were compared during the follow-up period between patients who experienced epilepsy recurrence and those who did not. We also assessed the correlation between inflammatory mediators and the time interval until the next recurrence.
RESULTS: Over a median 4-month follow-up period, 41 patients experienced seizure recurrence. Differences in interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) levels were observed between seizure recurrence and non-recurrence groups. After adjusting for covariates through multivariate Cox regression analysis, the patients in the third IL-6 tertile (>2.31 pg/mL; HR: 2.49; 95 % CI: 1.00-6.16; P = 0.049) and in the third TNF-α tertile (>0.74 pg/mL; HR: 2.80; 95 % CI: 1.13-6.92; P = 0.026) had higher risk of seizure recurrence. The time until the next recurrence was negatively correlated with IL-6 level (ρ =  - 0.392, P = 0.011).
CONCLUSION: High levels of IL-6 and TNF-α are associated with a higher possibility of seizure recurrence. Future predictive models should also include inflammatory mediators in addition to clinical variables.
BACKGROUND: Hypertension, sleep disorders, and depression represent notable public health issues, and their interconnected nature has long been acknowledged. The objective of this study is to explore the interplay between sleep disorders and depression in the context of hypertension.
METHODS: This cross-sectional study involved 42,143 participants aged 18 and above from the NHANES database across seven survey cycles between 2005 and 2018. After excluding those with missing data on depression, sleep disorders, and hypertension, as well as incomplete main variables, 33,383 participants remained. We used weighted logistic regression to examine the relationship between sleep disorders, depression, and hypertension. Additionally, we assessed the interaction between sleep disorders and depression on hypertension using both multiplicative and additive approaches to quantify their combined effect.
RESULTS: Compared to individuals without sleep disorders, those with sleep disorders have an increased risk of hypertension (OR = 1.51, 95% CI: 1.37-1.67). Furthermore, individuals with depression experience a significantly higher risk of hypertension compared to those with sleep disorders alone (OR = 2.34, 95% CI: 1.95-2.80). Our study reveals a positive interaction between sleep disorders and depression in relation to hypertension risk (OR = 1.07, 95% CI: 1.02-1.13). In addition, we observed the quantitative additive interaction indicators (RERI = 0.73, 95% CI: 0.56 ~ 0.92; API = 0.31, 95% CI: 0.11 ~ 0.46; SI = 2.19, 95% CI: 1.08-3.46) influencing hypertension risk. Furthermore, our research also identified that individuals with less than 7 h of sleep, a sleep latency period between 5 and 30 min, or a latency period exceeding 30 min experience a significantly increased risk of hypertension.
CONCLUSIONS: Our research uncovered separate links between sleep disorders, depression, and hypertension prevalence. Moreover, we identified an interaction between depression and sleep disorders in hypertension prevalence. Enhancing mental well-being and tackling sleep disorders could help prevent and manage hypertension. Yet, more investigation is required to establish causation and clarify mechanisms.
The hand position will be so that hands should be placed on the posterolateral side of the hemi thorax while the second hand will be at anterior chest extending from the lower ribs to above clavicle. In squeezing phase, in full expiration position, 3-4 chest wall compressions are applied to increase the expiratory flow rate to remove air trapped in lungs and mobilize secretions. This phase lasts only for 4-6 seconds. Chest wall compressions should be gentle and in comfortable position In release phase of lung squeezing technique at the end of expiration the compressed thoracic segment is quickly released. It increases the Trans pulmonary pressure and it opens the obstructed airways by plugging the mucus from small airways. creates the negative traction force on small airways which mobilize the thick and sticky mucus. The duration of each session will be of 20 minutes, 3 sessions per week for the periods of 4 weeks.
The ecological risk posed by MCs-producing M. aeruginosa and elevated ammonia to fish in actual aquatic environments remains uncertain. To address this knowledge gap, we conducted simulations to investigate the endocrine-reproductive toxicity of prolonged exposure (45 d) to Microcystis aeruginosa (2 × 10^6 cells/mL) and 30 mg/L total ammonia nitrogen (TAN) in zebrafish under environmentally relevant conditions. Our results showed that exposure to M. aeruginosa significantly inhibited the body weight, increased gonadosomatic index (GSI), delayed oocyte development, and disrupted endocrine hormonal balance (reduced gonadotropin-releasing hormone (GnRH), and increased estradiol (E2) and testosterone (T)). Mechanistically, it should be attributed to the over-expression of hypothalamic-pituitary-gonadal-liver (HPGL) axis-related genes (cyp11a and cyp17) induced by M. aeruginosa. On the other hand, TAN exposure caused mild damage to zebrafish ovarian tissue and promoted an increase of T levels by inducing the upregulation of steroid hormone synthesis gene (3βhsd) expression in the ovary. It is worth noting that the dysregulation of E2/T ratio in zebrafish ovaries may be attributed to the inhibition of cyp19a1a by both M. aeruginosa and TAN. These results were further confirmed by changes in steroidogenic enzymes activities in the M. aeruginosa or TAN treated groups. Our findings indicated that exposure to M. aeruginosa and TAN had adverse impacts on the reproductive system of zebrafish. And the combined exposure of M. aeruginosa and TAN had more severe effects on the body weight, GSI, pathological changes, hormone levels and HPGL-axis related gene expression in female zebrafish. These results provide compelling evidence regarding the potential risks for reproductive health associated with M. aeruginosa and TAN in eutrophic water bodies experiencing M. aeruginosa blooms, and contribute to the development of effective strategies for monitoring and managing these toxins in aquatic ecosystems.
The study is designed as a hospital-based cohort study at the pediatric ward of Kisantu general referral hospital. The investigators foresee a study inclusion period of 5 months. The study period is currently determined as such that it includes approximately 2 months of the dry season and 3 months of the rainy season. Seasonality is taken into account, because the rain affects the condition of the road and local disease epidemiology and can thus influence the study results. Most data will be collected retrospectively, i.e. all data on the health itinerary collected from the questionnaire and referral letter and the data from the health records in the referring health centers. Only the data from the in-hospital laboratory tests and clinical outcome will be collected prospectively.

The data from the health records at referring health centers will be consulted after termination of the five months study inclusion period to avoid any influence from the study in the patient management at health centers during the study.
The present invention provides an external medicine for treating scald and burn and a production method and the application of the external medicine. The external medicine is made by that earthworm is soaked in sugar to take liquid, and iron ruukki, diverse wormwood herb, alose and pearl are used. The formula is respectively soaked in oil or wine to obtain physic liquid, and the physic liquid is clarified and is filled in small calabash-shaped bottles, each small bottle is filled in one small box, and ten small boxes are filled in a big box. The physic liquid is divided into a No. 1 medicine and a No. 2 medicine, and the name is a soup fire good medicine for treating burning injury and water scalding. The present invention can rapidly restrict the strong pain of scald and burn, and heal affected parts of which the skin is rotten. The present invention can be applied to outer wounds and healing, and ophthalmalgia and skin scorching pain after irradiation by the strong light of electric welding and sore-sore toxin heat frying mosquito bite medicine.
Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
H7N9 viruses caused an outbreak of severe respiratory disease in China in 2013-2014, which was associated with severe respiratory illness, acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admissions, and death. The outbreak affected older adults and highlighted the need for a vaccine that is effective in this population. Prior studies have demonstrated the safety and immunogenicity of a vaccination regimen in which administration of the experimental H7N9 vaccine (H7N9 Anhui 2013/AA ca) was followed by an H7N9 inactivated vaccine in younger adults. This study will evaluate the safety and immunogenicity of a similar vaccination regimen in healthy adults, 50 to 70 years old, who are H7N9 seronegative.

Participants will be admitted to the inpatient unit 2 days before they will receive their first vaccination with the H7N9 Anhui 2013/AA ca vaccine. All participants will receive one dose of the H7N9 vaccine, delivered as a nasal spray, on Day 0. While in the inpatient unit, study procedures will include physical examinations, medical history reviews, nasal swabs, and blood and urine collections. On Day 9, participants will be discharged from the inpatient unit provided they meet certain medical criteria. If not, they will remain in the isolation unit until the criteria are met.

On Day 26, participants will be readmitted to the inpatient unit, and on Day 28, they will receive one dose of the H7N9 vaccine delivered as a nasal spray. Participants will remain in the inpatient unit until Day 37 and will take part in all of the same study procedures that occurred during the first inpatient stay. On Day 56, all participants will attend a study visit for a blood collection and nasal swab. On Day 98, all participants will receive one dose of the inactivated subvirion H7N9 vaccine. They will attend study visits on Days 101, 105, 112, 126, 154, and 180, which will include the same study procedures that occurred during the inpatient visits.
The invention discloses a cosmetic containing an earthworm active protein. The cosmetic containing the earthworm active protein comprises main materials and auxiliary materials. The main materials are composed of glycerinum, hyaluronic acid, aloe vera gel, trehalose, water soluble vitamin E, germall plus liquid, the earthworm active protein, a ginseng extracting solution and purified water. The auxiliary materials are one or more of essences, emulsifiers, water soluble jojoba oil, grapes seed oil, carbomer and triethanolamine allantoin. The cosmetic containing the earthworm active protein can be made into toning lotions, wrinkle removing essences, emulsions, face cream and masks according to difference of the selected auxiliary materials. The cosmetic containing the earthworm active protein has the functions of softening and smoothening the skin, moisturizing the skin and delaying senility, and can be used as a skin care product to be directly applied to the skin.
The present invention relates to an amphiphilic chitosan derivative and an emulsion material comprising the same. The chitosan derivative of the present invention is modified with a carboxymethyl group and a hexanoyl group and thus has amphiphilic properties. The chitosan derivative has excellent emulsifying properties and thus can be used as a material for a drug carrier. The chitosan derivative is represented by chemical formula 1. R_1 is CH_2COOH or H. R_2 is CO(CH_2)_4CH_3, CH_2COOH, COCH_3 or H. M represents an integer of 10-1,000. The drug carrier has a formulation of liposome, a micelle, emulsion, or a nanoparticle.
BACKGROUND AND PURPOSE: Slowly expanding lesions (SELs) have been proposed as novel MRI markers of chronic active lesions in multiple sclerosis (MS). However, the mechanism through which SELs affect brain volume loss in patients with MS remains unknown. Additionally, the prevalence and significance of SELs in Asian patients with MS remain unclear. This study aimed to investigate the association between SELs and no evidence of disease activity (NEDA)-3 status as well as brain volume loss in Japanese patients.
METHODS: A total of 99 patients with relapse-onset MS were retrospectively evaluated. SELs were identified on brain MRI based on local deformation when consecutive scans were registered longitudinally. We developed a logistic regression model and generalized linear mixed models (GLMMs) to evaluate the association between the number of SELs and disease activity and changes in brain volume.
RESULTS: During the observation period (2.0 ± 0.22 years), 35 patients developed at least one SEL. Multivariable logistic regression analysis showed that ≥2 SELs were associated with 0.2 times the risk of achieving a NEDA-3 status. GLMMs revealed that the number of SELs was negatively associated with volume changes in the cortex (p = .00169) and subcortical gray matter (p = .00964) after correction for multiple comparisons.
CONCLUSION: SELs were identified in Japanese patients with MS during the 2-year observation period. The number of SELs is associated with disease activity and brain volume loss, suggesting that the number of SELs could be a biomarker of disease activity in MS.
Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
INTRODUCTION: While CAR T-cell therapy has led to remarkable responses in relapsed B-cell hematologic malignancies, only 50% of patients ultimately have a complete, sustained response. Understanding the mechanisms of resistance and relapse after CAR T-cell therapy is crucial to future development and improving outcomes.
AREAS COVERED: We review reasons for both primary resistance and relapse after CAR T-cell therapies. Reasons for primary failure include CAR T-cell manufacturing problems, suboptimal fitness of autologous T-cells themselves, and intrinsic features of the underlying cancer and tumor microenvironment. Relapse after initial response to CAR T-cell therapy may be antigen-positive, due to CAR T-cell exhaustion or limited persistence, or antigen-negative, due to antigen-modulation on the target cells. Finally, we discuss ongoing efforts to overcome resistance to CAR T-cell therapy with enhanced CAR constructs, manufacturing methods, alternate cell types, combinatorial strategies, and optimization of both pre-infusion conditioning regimens and post-infusion consolidative strategies.
EXPERT OPINION: There is a continued need for novel approaches to CAR T-cell therapy for both hematologic and solid malignancies to obtain sustained remissions. Opportunities for improvement include development of new targets, optimally combining existing CAR T-cell therapies, and defining the role for adjunctive immune modulators and stem cell transplant in enhancing long-term survival.
According to this invention, plants of the genus  Triodia  are harvested for use as a renewable energy source or as a means of carbon sequestration.  Triodia  is a hummock-forming grass endemic to Australia, commonly known as spinifex. It is an abundant perennial plant which grows in semi-arid and arid regions. The novel use of  Triodia  as a biofuel feedstock has many advantages over the prior art. Being perennial, there is no need to plant and fertilise crops. The plants can be continuously harvested without damaging the soil.  Triodia  grows well with even small amounts of natural rainfall.